SGD Pharma maintains its presence in Spain |

The Sucy-en-Brie factory, 400 employees, has been dedicated to producing pharmaceutical bottles since 1917. The factory supplies syrups, droppers, tablets, injectable and infusion bottles to over 450 customers around the world and cover the following therapeutic areas: oral and parenteral antibiotics, parenteral nutrition, respiratory illness, pain-relievers, anesthetics, and OTC. Every year, 80,000 tons of Type II & III flint and amber molded glass bottles are produced there, making this factory one of the biggest players in the European health care industry. Its 41,000 m² surface includes ISO 8 clean rooms, two furnaces, and 8 production lines. The factory is ISO 15378 & 50001 certified.

Paris, October 24, 2018 – SGD Pharma, a global leader in glass pharmaceutical packaging, has announced the appointment of Christophe Nicoli as the group’s new Chief Executive Officer (CEO), succeeding Juergen Sackhoff.

Michel Giannuzzi, Chairman and Chief Executive Officer of the Verallia Group – one of Europe’s leading glass packaging manufacturers for the food and beverage sector - has been elected Vice-President of FEVE – the European Container Glass Federation - at its FEVE General Meeting in Rotterdam on June 15th.

SGD Pharma is expanding its offering to include premium products for the Asian markets – with Phoenix, a new range of high-quality glass containers. The range, which is manufactured in China to international standards, offers top cosmetic quality.

SGD Pharma's Zhanjiang (China) plant produces 1.2 million Type II & III flint molded glass vials daily for the parenteral market and for health care beauty products. With a surface of 85,000 m2, the plant included a glass furnace, 6 production lines, an ISO 8 clean room of 2,000 m², a resorting room and a customization workshop. Early 2018, SGD Pharma invested 7 million Euros to improve the automation and the production, including the rebuilding of the furnace, to make the Zhanjiang plant an exemplary production center.

Clareo vials from SGD Pharma offer a combination of homogeneous wall thickness and superior cosmetic quality, which for molded glass Type II is unique in the market. The new range offers technical characteristics similar to the vials in the existing range and can replace them without any regulatory change. Once again, SGD Pharma demonstrates with Clareo its expertise in the control of manufacturing process of molded glass.